Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Expected to Post Quarterly Sales of $154.71 Million

Equities research analysts forecast that Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating) will report sales of $154.71 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Supernus Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $150.31 million and the highest estimate coming in at $159.10 million. Supernus Pharmaceuticals posted sales of $130.93 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 18.2%. The business is expected to report its next earnings report after the market closes on Monday, January 1st.

On average, analysts expect that Supernus Pharmaceuticals will report full year sales of $676.84 million for the current year, with estimates ranging from $670.40 million to $683.28 million. For the next financial year, analysts expect that the company will report sales of $610.13 million, with estimates ranging from $600.12 million to $629.18 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPNGet Rating) last announced its quarterly earnings data on Wednesday, April 13th. The specialty pharmaceutical company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.25). Supernus Pharmaceuticals had a net margin of 9.21% and a return on equity of 6.75%.

A number of equities research analysts have issued reports on SUPN shares. TheStreet downgraded Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Monday, April 18th. StockNews.com upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, April 18th. Finally, Zacks Investment Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, March 4th.

SUPN opened at $27.48 on Friday. Supernus Pharmaceuticals has a 1 year low of $23.15 and a 1 year high of $34.50. The stock has a 50-day moving average price of $30.71 and a 200-day moving average price of $30.68. The firm has a market cap of $1.47 billion, a PE ratio of 28.04 and a beta of 1.12. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.91 and a quick ratio of 1.63.

Institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada increased its position in shares of Supernus Pharmaceuticals by 69.0% during the 2nd quarter. Royal Bank of Canada now owns 4,491 shares of the specialty pharmaceutical company’s stock valued at $138,000 after purchasing an additional 1,833 shares during the last quarter. Commonwealth Equity Services LLC increased its position in shares of Supernus Pharmaceuticals by 14.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 11,380 shares of the specialty pharmaceutical company’s stock valued at $303,000 after purchasing an additional 1,440 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Supernus Pharmaceuticals by 9.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 24,083 shares of the specialty pharmaceutical company’s stock valued at $642,000 after purchasing an additional 1,984 shares during the last quarter. Truist Financial Corp bought a new position in shares of Supernus Pharmaceuticals during the 3rd quarter valued at approximately $489,000. Finally, Swiss National Bank increased its position in shares of Supernus Pharmaceuticals by 0.9% during the 3rd quarter. Swiss National Bank now owns 117,100 shares of the specialty pharmaceutical company’s stock valued at $3,123,000 after purchasing an additional 1,000 shares during the last quarter.

Supernus Pharmaceuticals Company Profile (Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

Featured Articles

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.